Compare ADMA Biologics Inc (ADMA) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Open Text Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Open Text Corporation trades at $22.6 (market cap $5.65B). The key difference: Open Text Corporation is far larger — about 2.7× ADMA Biologics Inc's market cap, and Open Text Corporation pays a 4.72% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | OTEX | |
|---|---|---|
Market Cap | $2.13B | $5.65B |
Sector | Health | Technology |
52-Week High | $20.38 | $39.69 |
52-Week Low | $7.60 | $20.01 |
Enterprise Value | $2.20B | $10.81B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OTEX trades at $22.57, down 2.04% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.95 and net income margin of 9.91%, supported by recent earnings beats. Recent news highlights strategic investments in AI and sovereign cloud in Europe, alongside a dividend payment scheduled for June 19, 2026.
The outlook is mixed; analyst consensus targets $29.75 (31.8% upside) with 42% buy ratings, but technical indicators suggest near-term pressure. Risks include execution of growth initiatives and market volatility. The stock presents a value opportunity if AI investments drive future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
